Doxorubicin and DTIC in organ transplant recipients with metastastic soft tissue sarcoma

19502 Background: The development of cancer in organ transplant recipients is well known. Depressed immunosurveillance induced by the use of immunosuppressive agents for prevention of rejection is a causative factor. Kaposi’s sarcoma (KS), non-Hodgkin lymphoma and nonmelanoma skin cancers are more than 20-fold increased than in general population, EBV, HSV and HHV-8 seem to be causative. Other soft tissue sarcoma (STS) than KS are extremely rare post-organ transplantation tumours. Methods: Due to the fact that there is no “standard therapy” in organ transplanted STS patients we studied the feasibility, toxicity and response to a chemotherapy with doxorubicin (75 mg/m2, d1) and dacarbacine (DTIC, 300 mg/m2, d1–4). Two patients with metastatic disease (histology: poor differentiated uterine stromal sarcoma, poor differentiated malignant peripheral nerve sheath tumour, each n=1) were treated with up to 6 cycles of therapy. Results: One patient achieved a partial remission and dramatic improvement in life qua...